Myricx Bio

Myricx Bio is a UK biotech company developing a novel class of payloads for antibody-drug conjugates (ADCs) based on N-myristoyltransferase inhibitors (NMTis). These ADCs target cancer cell survival, addressing unmet needs in oncology with demonstrated preclinical efficacy and safety. The company is a spinout from Imperial College London and the Francis Crick Institute.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $114M

Date: 08-Jul-2024

Investors: Novo Holdings, Abingworth, British Patient Capital, Eli Lilly & Company, Sofinnova Partners, Brandon Capital

Markets: Biotechnology, Oncology, Pharmaceuticals, Life Science, Therapeutics

HQ: London, England, United Kingdom

Founded: 2019

Website: https://myricxbio.com/

LinkedIn: https://www.linkedin.com/company/myricx-bio

Twitter:

Instagram: